A maintenance regimen using an intravenous immunoglobulin (IVIG) therapy may reduce disease severity and improve function in people with generalized myasthenia gravis, according to data from a Phase 2 clinical trial. IVIG is commonly used to treat acute symptom worsening in people with myasthenia gravis (MG). The …
Long-term use of the immunosuppressant tacrolimus was found to be safe and effective in myasthenia gravis (MG) patients with self-reactive antibodies targeting muscle-specific kinase, or MuSK — a protein important in nerve-muscle communication — according to the findings of a new study by researchers in China. Treatment with tacrolimus significantly…
The European Medicines Agency granted orphan drug status to the experimental cell therapy KYV-101 to treat myasthenia gravis (MG). The designation is given to medicines that aim to treat life-threatening or chronic debilitating conditions affecting no more than five in every 10,000 people. It provides companies with several…
Soliris (eculizumab) effectively eased disease severity and reduced the need for immunosuppressive therapies in people with treatment-resistant generalized myasthenia gravis with anti-AChR antibodies, a real-world study in Italy shows. The treatment also reduced the number of disease exacerbations that required rescue therapy, such as intravenous immunoglobulin (IVIG)…
Many adults with myasthenia gravis (MG) need intensive treatment in the first year after diagnosis, with younger patients and women facing a higher risk of death as the disease progresses, a study found. The researchers said the results point to a need for better treatment options. The study, “…
Cartesian Therapeutics is planning to launch a pivotal, Phase 3 clinical trial of its experimental cell therapy Descartes-08 in people with myasthenia gravis (MG), following positive data from an ongoing Phase 2 study in patients. The company announced that it recently completed a meeting with the…
A machine learning model taking into account markers of inflammation and clinical data may accurately predict whether people with generalized myasthenia gravis (gMG) are likely to see their disease symptoms ease after six months of standard treatment. Researchers described the new tool in the study, “Interpretable…
Myasthenia gravis (MG) patients who are women or have a tumor in the thymus gland are more likely to require intensive care due to disease exacerbation, a retrospective study in Finland suggests. Patients with late-onset disease in whom disease symptoms become apparent after the age of 50 were also…
The first patient has been dosed in a proof-of-concept clinical trial evaluating CNP-106, an immune-modifying nanoparticle that’s designed to reprogram the immune system in people with generalized myasthenia gravis (gMG). The Phase 1b/2a trial NCT06106672), sponsored by CNP-106’s developer Cour Pharmaceuticals, will assess the safety, tolerability, efficacy,…
The China National Food and Drug Administration has accepted and placed under priority review an application from Remegen seeking approval of telitacicept as a treatment for generalized myasthenia gravis (gMG). That’s according to a press release from Remegen, a commercial-stage biotechnology company that’s developing the treatment…
Get regular updates to your inbox.
